Opportunity Information: Apply for RFA FD 16 003
Apply for RFA FD 16 003
- The Food Drug Administration in the consumer protection food and nutrition health sector is offering a public funding opportunity titled "Building towards Statistically Based Pharmaceutical Quality Standards (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.103 Food and Drug AdministrationResearch.
- This funding opportunity was created on Jul 31, 2015 and posted on Jul 31, 2015.
- Applicants must submit their applications by Oct 16, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts County governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Public housing authorities/Indian housing authorities Private institutions of higher education State governments Others (see text field entitled Additional Information on Eligibility for clarification).
- Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Funding Opportunity Announcement titled "Building towards Statistically Based Pharmaceutical Quality Standards (U01)" (RFA-FD-16-003) is an FDA cooperative agreement program aimed at strengthening how pharmaceutical quality decisions are made by grounding them in solid statistical evidence. The core purpose is to generate real-world data and then use those data to design practical statistical sampling and analysis strategies that can directly support FDA/CDER policy development. In plain terms, FDA is looking for projects that can help it write clearer, data-driven guidance on which statistical tools should be used in pharmaceutical manufacturing quality assessments, especially when deciding whether a manufactured lot (batch) should be released for distribution.
A major emphasis of the opportunity is the development of statistical standards and methods that are appropriate for lot release. Lot release decisions sit at a critical point between manufacturing and patient use, and they often rely on sampling plans (how many units to test, from where, and how often) and acceptance criteria (what constitutes "passing"). FDA is seeking approaches that are not only mathematically sound, but also realistic for industry use and meaningful for risk control. The broader intent is to push the field toward deeper product and process understanding across the entire product lifecycle, rather than treating quality as something checked only through end-product testing. By improving statistical approaches, the program aims to support more modern, science-based manufacturing oversight where process knowledge, variability control, and risk-based decision making are central.
The projects funded under this announcement are expected to produce data, propose sampling frameworks, and demonstrate analysis methods that can inform both regulators and the human pharmaceutical industry. That includes producing evidence and examples that show how different statistical plans perform under different manufacturing conditions, how they detect meaningful shifts or failures, and how they balance patient risk, manufacturing variability, and practical feasibility. FDA also signals that the work can be organized into smaller, focused subsets to make the results more interpretable and applicable. Examples of how projects might be split include differences by product type (for example, solid oral dosage forms versus sterile injectables), process type (continuous versus batch manufacturing), manufacturing complexity (simple versus highly complex processes), and therapeutic index (narrow therapeutic index products where small deviations can have larger clinical consequences). That structure suggests FDA is looking for outputs that can translate into tailored standards rather than one-size-fits-all recommendations.
From an administrative standpoint, this is a discretionary funding opportunity using a cooperative agreement mechanism (U01). A cooperative agreement typically means FDA expects to have substantial involvement during the project, such as collaboration on project direction, milestones, deliverables, and alignment with regulatory needs, rather than functioning as a hands-off funder. The program was posted July 31, 2015, with an application deadline of October 16, 2015, and it was later archived on November 15, 2015. The estimated total funding was $2,000,000 with an award ceiling of $1,000,000, and FDA anticipated making about two awards, implying projects were expected to be substantial in scope and capable of producing actionable outputs.
Eligibility was broad and included many domestic applicant types such as public and private institutions of higher education, nonprofits (including those without 501(c)(3) status), various levels of government entities, tribal governments and organizations, for-profit organizations (including small businesses), and others as specified in the full announcement. Importantly, the announcement explicitly allowed foreign participation: non-U.S. entities could apply, non-U.S. components of U.S. organizations were eligible, and foreign components (as defined by HHS policy) were permitted. There was no cost sharing or matching requirement listed, lowering the barrier to participation for applicants who could contribute expertise and data but might not have additional funds to commit.
Overall, the opportunity is best understood as an FDA effort to build the statistical backbone for future pharmaceutical quality standards. Rather than funding basic research disconnected from regulatory practice, the intent is to create evidence, sampling plans, and analytical approaches that can be translated into FDA/CDER guidance and, in turn, drive consistent industry adoption of risk-based, science-based statistical methods for manufacturing control and lot release. For applicants, the most competitive projects would likely have combined strong statistical expertise with practical pharmaceutical manufacturing understanding, access to relevant datasets or the ability to generate them, and a clear plan for producing outputs that regulators and manufacturers can actually implement. For questions or technical issues accessing the full announcement, the listed grants management contact was Lisa Ko at lisa.ko@fda.hhs.gov, and the full notice was hosted through the NIH Guide for Grants and Contracts.
FAQs: Building towards Statistically Based Pharmaceutical Quality Standards (U01) (RFA-FD-16-003)
What is the title and identifier of this funding opportunity?
The Funding Opportunity Announcement (FOA) is titled "Building towards Statistically Based Pharmaceutical Quality Standards (U01)" and is identified as RFA-FD-16-003.
Which federal agency is offering this opportunity?
This is an FDA funding opportunity. The program is described as supporting FDA/CDER policy development related to pharmaceutical quality.
What is the main goal of this cooperative agreement?
The core purpose is to generate real-world data and use those data to design practical statistical sampling and analysis strategies that can directly support FDA/CDER policy development. The overall intent is to strengthen pharmaceutical quality decisions by grounding them in solid statistical evidence.
What does FDA mean by "statistically based pharmaceutical quality standards" in this context?
In this announcement, the focus is on building evidence and workable statistical methods (including sampling plans and analysis approaches) that can be translated into clearer, data-driven recommendations on which statistical tools should be used in pharmaceutical manufacturing quality assessments.
What types of regulatory or industry decisions is the FOA trying to improve?
A major emphasis is improving statistical approaches used in lot (batch) release decisions, including how sampling plans and acceptance criteria are set and evaluated.
What is "lot release" and why is it emphasized?
Lot release refers to the decision point where a manufactured lot (batch) is evaluated to determine whether it should be released for distribution. The FOA emphasizes lot release because it is a critical link between manufacturing and patient use and often depends on statistical sampling and acceptance decisions.
What kinds of statistical work does FDA appear to be looking for?
Projects are expected to produce data, propose sampling frameworks, and demonstrate analysis methods that show how statistical plans perform under different manufacturing conditions, how they detect meaningful shifts or failures, and how they balance patient risk, manufacturing variability, and feasibility for real-world use.
Is this opportunity focused on end-product testing only?
No. The broader intent is to support deeper product and process understanding across the entire product lifecycle, rather than treating quality as something checked only through end-product testing. The FOA frames this as supporting more modern, science-based manufacturing oversight where process knowledge, variability control, and risk-based decision making are central.
What kinds of outputs are expected from funded projects?
Based on the FOA description, expected outputs include real-world datasets or generated data, proposed sampling frameworks, and demonstrated statistical analysis methods with evidence and examples that can inform regulators and the human pharmaceutical industry and support FDA/CDER policy development.
Does the FOA encourage tailoring approaches to different manufacturing scenarios?
Yes. The announcement suggests organizing work into smaller, focused subsets to make results more interpretable and applicable, implying that tailored standards (rather than one-size-fits-all) are desirable where appropriate.
What are examples of how a project could be divided into subsets?
The FOA gives examples such as differences by product type (e.g., solid oral dosage forms vs. sterile injectables), process type (continuous vs. batch manufacturing), manufacturing complexity (simple vs. highly complex processes), and therapeutic index (including narrow therapeutic index products).
What funding mechanism is used?
This opportunity uses a cooperative agreement mechanism (U01).
What does a U01 cooperative agreement imply about FDA's role during the project?
A cooperative agreement typically indicates substantial involvement by FDA during the project, such as collaboration on project direction, milestones, deliverables, and alignment with regulatory needs, rather than a hands-off relationship.
Is this a discretionary funding opportunity?
Yes. The FOA is described as a discretionary funding opportunity.
When was the opportunity posted, and what were the key dates?
The program was posted on July 31, 2015. The application deadline was October 16, 2015. The opportunity was later archived on November 15, 2015.
How much total funding was estimated, and what was the maximum award size?
The estimated total funding was $2,000,000. The award ceiling was $1,000,000.
How many awards did FDA anticipate making?
FDA anticipated making about two awards.
What does the combination of total funding, ceiling, and expected number of awards suggest about project scope?
It implies projects were expected to be substantial in scope and capable of producing actionable outputs that could translate into policy or guidance-relevant statistical standards and methods.
Who was eligible to apply?
Eligibility was broad and included many domestic applicant types such as public and private institutions of higher education, nonprofits (including those without 501(c)(3) status), various government entities at multiple levels, tribal governments and organizations, for-profit organizations (including small businesses), and others as specified in the full announcement.
Were for-profit organizations allowed to apply?
Yes. For-profit organizations, including small businesses, were included among the eligible applicant types.
Were nonprofit organizations required to have 501(c)(3) status?
No. The eligibility description explicitly includes nonprofits, including those without 501(c)(3) status.
Is foreign participation allowed?
Yes. The announcement explicitly allowed foreign participation, including non-U.S. entities, non-U.S. components of U.S. organizations, and foreign components (as defined by HHS policy).
Was cost sharing or matching required?
No. The FOA indicates there was no cost sharing or matching requirement.
Where was the full notice hosted?
The full notice was hosted through the NIH Guide for Grants and Contracts.
Who was the grants management contact listed for questions or technical issues?
The listed grants management contact was Lisa Ko. The email provided was lisa.ko@fda.hhs.gov.
What is the overall "big picture" intent of the program?
The opportunity is positioned as an FDA effort to build the statistical backbone for future pharmaceutical quality standards by producing evidence, sampling plans, and analytical approaches that can be translated into FDA/CDER guidance and drive consistent industry adoption of risk-based, science-based statistical methods for manufacturing control and lot release.
Browse more opportunities from the same category: Consumer Protection Food and Nutrition Health
Next opportunity: Promote and Enhance River Conservation and Management
Previous opportunity: Expanding and updating Rocky Intertidal Monitoring Protocols for West Coast Parks
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA FD 16 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA FD 16 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Evaluating Quality Metrics for Risk Based Surveillance of Drug Manufacturing Operations and Facilities (U01) Apply for RFA FD 16 004 Funding Number: RFA FD 16 004 Agency: Food Drug Administration Category: Consumer Protection Food and Nutrition Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA FD 16 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.